The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeutics. This report presents the results of pre-clinical assessment of a lipoplex comprising a plasmid-encoded, modular bi-functional shRNA (bi-shRNA), which executes selective and multi-mutant allelic KRAS G12mut gene silencing, encased 
Background
Pancreatic ductal adenocarcinoma (PDAC) is a disease characterized by early metastatic spread and high mortality. There has been limited benefit from the incremental changes in therapy of PDAC over the past 40 years despite an increased understanding of the genetic, epigenetic, biochemical and micro-environmental processes of this malignancy [1] [2] [3] [4] . Mutations involving the proto-oncogene KRAS and tumor suppressors CDKN2A, TP53 and SMAD4 are the major genetic signal alterations responsible for malignant phenotype [2, 5, 6] . More than 90% of PDAC's contain KRAS activating mutations, the majority of which are at codon G12 (COSMIC database). These mutated RAS family genes are key "pro-cancer" regulators of the RAF/MEK/ERK, PI3K/AKT/mTOR and RalA/B signaling pathways [4, 7] . Recently, in vitro and in vivo targeting of MEK, ERK, PI3K and mTOR in pancreatic cancer have shown promising results based on their ability to impede cellular growth or delay tumor formation. Several clinical trials have been initiated based on these results (NCI-2016-01356) [2, [8] [9] [10] . However, a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 combinatorial toxicity and therapy-induced cross activation of collateral signaling pathways underscore the complexities of targeting the RAS downstream signaling pathway [3, 11, 12] . Murine models confirm the oncogenic driver status of KRAS mutation (KRAS mut ) in PDAC in conjunction with the stepwise accumulation of additional genetic changes. Obstacles to effective direct targeting of KRAS mut include a lack of well-defined binding pockets ("undruggability"), ineffective systemic delivery of RNA interference (RNAi) moieties and heretofore the lack of RNAi KRAS mut /KRAS wt selectivity [1, 13, 14] .
We report the results of pre-clinical assessment of a lipoplex comprising a plasmid encoded bi-functional shRNA (bi-shRNA) that executes selective KRAS mut gene silencing encased within a fusogenic liposome systemic delivery vehicle. The unique mechanism of action of bishRNA has been described previously [15] . Briefly, the bi-shRNA-KRAS mut consists of two stem-loop structures with a miR-17-92 backbone; the first stem-loop structure is composed of complementary guide and passenger strands, while the second stem-loop structure has strategic base pairing mismatches at key positions on the passenger strand. The encoding plasmid is able to accommodate mature shRNA loading onto more than one type of RNA-induced silencing complex (RISC) to effect both mRNA cleavage (via cleavage-dependent Ago2-loaded RISC) and mRNA degradation, p-body sequestration, and inhibition of translation (mediated by cleavage-independent Ago1-4-loaded RISC). Herein, using the PANC1 pancreatic cancer tumor model in vitro and in vivo, we demonstrate that KRAS mut specific targeting with bishRNA-KRAS mut effectively and selectively suppresses KRAS mut expression and re-activates receptor tyrosine kinase (i.e., EGFR) signaling activity. This is the first demonstration of effective mutant-selective knockdown of KRAS in vivo with a systemically delivered therapeutic modality.
Materials and methods

Materials and cell cultures
HEK293, PANC-1 cells and ASPC-1 cells were purchased from ATCC (Manassas, VA). pSi-CHECK vector was purchased from Promega (Madison, WI). HEK293 and PANC-1 cells were cultured in DMEM medium with 10% FBS, 2 mM Glutamine. ASPC-1 cells were cultured in RPMI-1640 medium with 10% FBS, 2 mM Glutamine. All cells were incubated in humidified incubator at 37˚C with 5% CO2.
first; after quantifying the firefly luminescence, this reaction was quenched, and the Renilla luciferase reaction was simultaneously initiated by adding Stop & Glo1 Reagent to the same well. HEK293 cells were transfected by electroporation. Afterwards, cells were plated in 96-well plates in triplicate and assayed at 24, 48 or 72 hours post transfection. The fluorescence was read by Gemini XPS Microplate Reader (Molecular Device).
Cell viability assay
Cell viability was assayed using the CellTiter-Blue1 Luminescence Cell Viability Assay System from Promega (Madison, WI). Transfected cells or treated cells were plated in triplicate in 96-well plates and assayed at 24, 48 or 72 hours post transfection. Cells were lysed and assayed with reagents supplied by the assay system and the fluorescence was detected by using Luminoskan™ Ascent Microplate Luminometer (ThermoFisher Scientific).
DNA and DNA-Lipoplex
50 mg of research grade plasmid DNA was contract manufactured by Aldevron (Fargo, ND). The identity of manufactured plasmids was reconfirmed by restriction digest and by sequencing the insert region before DNA-lipoplex manufacturing. The lyophilized DNA-Lipoplex was manufactured according to the thin film Liposome method as previously published (Templeton, Nature Biotech 1997 and Phadke, DNA and Cell Biol 2011) with the following modifications: after the rotovap step to create the DOTAP:Cholesterol film, the product was resuspended in 10% sucrose and then manually extruded through successively smaller pore size filters to create the Liposomes. The Liposomes were mixed with DNA to create the DNALipoplex product and intermediate QC was performed to check specifications. The product was vialed, frozen, and lyophilized overnight. The following day, the freeze-dried product was sealed, labeled, and quarantined for QC/release. After the product was released and ready for use, the freeze-dried DNA-Lipoplex was reconstituted in 5% dextrose and extruded through a 1.0 μm filter. At this point, the product was ready for use and could be directly injected or diluted with additional 5% dextrose to the appropriate concentration prior to administration. improved detection sensitivity. 1μl of digested amplicons was loaded onto a DNA 1K chip and the fragments were visualized and analyzed by the Experion analysis software.
Plasmid detection and quantification
The mouse tissues were thoroughly homogenized using Qiagen TissueLyzer II. Tissue homogenate was then digested with proteinase K and the total DNA extracted using DNeasy Kit (Qiagen). The plasmid was detected and quantified using a home-developed qPCR assay. Briefly, 2ul of extracted total DNA was mixed with a BioRad IQ Supermix, a pUMVC3 forward primer, a pUMVC3 reverse prime and a TaqMan probe specifically recognizing the pUMVC3 amplicon. The 40 cycle qPCR program (using a BioRad CFX384 qPCR instrument) was set up using an automatic liquid handler. The DNA copy number was quantified by referring the Ct numbers to a standard curve.
In vivo mouse xenograft study
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Altogen Labs, Austin, TX (IACUC protocol 3-17836). Following modifications were made to the study "endpoint" definition: Moribund animals or tumor xenograft volumes of 2,000 mm 3 , or 40 days after xenotransplantation. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. Immune-compromised nude mice (9-to 11-week old females) were purchased from the Harlan laboratories. All animal procedures and maintenance were conducted in accordance with the institutional guidelines (Altogen Labs, Austin, TX). The maximum tumor size was 2,000 mm 3 . Animals were observed at 6-8 hours and 1 day after each injection for acute reaction; neither adverse reactions nor aberrant behavioral phenotypes were observed.
Observation and data collection
After tumor cells inoculation, the animals are checked daily for morbidity and mortality. At the time of routine monitoring, the animals are checked for any adverse effects of tumor growth and treatments on normal behavior such as mobility, visual estimation of food and water consumption, body weight gain/loss, eye/hair matting, pain/distress, self mutilation, and any other abnormal effects. Signs of graft rejection, infection, and unalleviated pain will be justification for immediate euthanasia as determined by the veterinarian.
Tumor volumes are measured every 3-4 days in two dimensions using an electronic caliper, and the volume data are expressed in mm 3 using the formula: V = 0. 
Group assignment
Before grouping and treatment, all animals are weighed and the tumor volumes confirmed (100-150mm
3 ) using electronic caliper. Since the tumor volume can affect the effectiveness of any given treatment, mice assigned into groups using randomized block design as following: First, the experimental animals are divided into homogeneous blocks based on their tumor volume. Secondly, within each block, randomization of experimental animals to different groups conducted. By using randomized block design to assign experimental animals, we ensure that each animal has the same probability of being assigned to any given treatment groups and therefore systematic error is minimized.
Clinical observations
There was no clinical signs or behavioral phenotype observed within the study (daily cage intensive observation for adverse effect were performed). No BWL>20% were observed in any of the groups (Fig 1) .
Tumor size was measured every 4 days. Animal body weight (g) was measured in subcutaneous PANC1 xenografts on days 7, 14, 21, 28, 35, 39 after tumor inoculation (Day 0); no significant changes were observed. At the end of study, animals were sacrificed by cervical dislocation. The pancreas carcinoma PANC1 (CRL-1469) cell line was obtained from ATCC and cultured in ATCC formulate Dulbecco's Modified Eagle's Medium (cat#302002) and supplemented with fetal bovine serum to a final concentration of 10% (ATCC). Subculturing was performed by trypsinization with 0.25% Trypsin-EDTA (2-3 minutes) and 1:4 split for every subsequent passage. The cell line was cultured at 37˚C / 5% CO 2 in a humidified incubator. Cells were mixed (1:1 volume) with Matrigel (BD Biosciences) and the suspension (50% matrigel) subcutaneously injected (1.0 x 10 6 cells per injection) on day 0 into the animal flank area to ensure successful tumor initiation and tumor growth measurements. Ninety animals were used for PANC-1 xenotransplantation and 78 animals with measurable tumors were selected on day 7 to be used for subsequent experiments. 10 animals per group (n = 6) were used for growth inhibition study and 3 animals per group (n = 6) were used for molecular analysis. Freeze-dried formulations used for this study were reconstituted immediately prior to each injection. Reconstitution was performed in a Biological Safety Cabinet. A 3 mL syringe and 16 G needle was used to transfer D5W into the vial containing the freeze-dried test article, which was then gently flicked to resuspend the test article (final concentration = 0.25 mg DNA/ml) and then finally filtered with a 1.0 μm PES syringe filter. The filtered test article was pooled and diluted with D5W to the final injection dose (200μl per animal).
The compound or control was Intravenously administered on day 7 post-inoculation when measurable tumor growth was detected with an average tumor size of 150 mm 3 . Study mice were randomly assigned to each study group with an equal distribution of tumor size per group. Each group comprised 13 animals. 10 of the animals were enrolled in tumor growth inhibition study. Measurements of tumor volume (mm 3 ) were performed by digital calipers every 4 days for 40 days post tumor inoculation. Animal body weight (g) was measured in subcutaneous PANC1 xenografts on days 7, 14, 21, 28, 35, 39 after tumor inoculation (Day 0). Remaining 3 animals in each group were sacrificed at day 27 (two days post last infusion) from which tumors were harvested for molecular analysis.
Western blot
To prepare total protein lysates, half of the PANC1 tumor tissue samples preserved in Allprotect Tissue Reagent (Qiagen) were first cut out and weighted, then ice cold CelLytic MT TM Cell Lysis Reagent for mammalian tissues (Sigma, St. Louis, MO) with 1 x protease inhibitors (Sigma), 1 x phosphatase inhibitors 2 (Sigma) and 1 x phosphatase inhibitors 3 (Sigma) was added at a ratio of 10 μL lysis buffer per 1 mg tumor sample. Tumor tissue was homogenized and incubated on ice for 30 minutes. The homogenates were centrifuged at 14,000 rpm for 10 min and the supernatants transferred to a clean tube. The protein concentration was measured using the Bradford method. 30 μg total protein lysate of each tumor sample was mixed with 1/ 3 volume of 4 x Laemmli Sample buffer (Bio-Rad, Hercules, CA) with 5% β-mercaptoethanol (Sigma) and denatured by heating, then loaded on 4-20% Mini-PROTEAN TGX gradient gel (Bio-Rad). After electrophoresis, the protein was transferred to a PVDF membrane using Trans-Blot Turbo system (Bio-Rad). To detect target protein, the membrane was first blocked with 5% Blotting-Grade Blocker (Bio-Rad), 0.1% Tween 20 (Sigma) in 1 × DPBS for 1 hour at room temperature on an orbital shaker, then probed with primary antibody, 1:1000 dilution, at 4˚C overnight in 5% Blotting-Grade Blocker (Bio-Rad), 0.1% Tween 20 in 1 × DPBS on orbital shaker. After washing the membrane with 0.1% Tween 20 in 1 × DPBS 3 times, 5 minutes each, the membrane was probed with HRP conjugated anti-mouse or rabbit 2 nd antibody (Santa Cruz) at 1:2000 dilution in 5% Blotting-Grade Blocker (Bio-Rad), 0.1% Tween 20 in 1 × DPBS for 2 hours on the orbital shaker. Then the membrane was washed three times with 0.1% Tween 20 in 1 × DPBS 3 times, 5 minutes each. The signal was detected using SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific) and captured using G-Box (Syngene). For phosphorylated proteins, primary antibody targeting to specific phosphorylated site was first probed, then the membrane was striped with Restore Western Blot Stripping Buffer (Thermo Scientific) for 10-15 minutes at room temperature. The effect of stripping was verified by confirming no residual signal using G-Box with SuperSignal West Dura Chemiluminescent Substrate for 15-30 minutes. Then the same membrane was probed with primary antibody targeting the total protein to visualize the amount of total protein. The densitometry of the protein signal was calculated using software Image J. The primary anti-
and anti-Ras (D2C1) were obtained from Cell Signaling (Boston, MA). Anti-phospho-EGFR (Y1125) was obtained from WuXi AppTec (San Diego, CA), anti-phospho-EGFR (Y1069, referred as Y1045 in this paper) from Upstate (Lake Placid, NY), and anti-GAPDH from Santa Cruz (Dallas, TX).
Results
Use of a dual luciferase reporter system to optimize KRAS mut mutant specific knockdown constructs
The psiCHECK2 reporter vector is a mammalian expression vector that expresses dual luciferase reporters on a single vector thereby allowing testing of two expressed sequences in the same environment under the same conditions. We inserted nucleotide sequences encoding the first 17 amino acids of KRAS into the regions encoding the amino terminal of the psi-CHECK2 vector luciferase reporter genes; i.e., the KRAS wt sequence was inserted into the renilla (RL) luciferase gene and a KRAS mut sequence was inserted into the firefly (FF) gene (see Fig 2A; for specific sequence insertion see S2A Fig) . A total of five psiCHECK2-based test vectors were constructed: G12D, G12C, G12V, G12R, and one for the wild-type sequence only (S2A Fig) . The test reporter constructs express a RL/FF ratio similar to the parent psiCHECK2 ( Fig 2B) . A single nucleotide G!A change leads to G12D mutation. Using tiling approach, we constructed a series of bi-shRNA knockdown vectors with the G12D mutation's single nucleotide change positioned at positions 2-11 of the guide strand ( Fig 2C, panel a) . We then cotransfected the G12D/WT dual expression test vector with the G12D specific knockdown vector and showed that positioning of the mutant sequence at different positions of the guide strand resulted in different FF/RL ratios ( Fig 2C, panel b) . Slight variations in the test vector to knockdown vector ratio showed similar reproducible results (S2B Fig). All subsequent studies were done with the test vector to knockdown vector at 1 to 1 ratio. An advantageous knocked down mutant:wild-type ratio was obtained with complement to mutated nucleotide in positions 2, 3, 4, 5, 9, 10 and 11 of the guide strand. Complement to mutated nucleotide at positions 2, 3 or 4 of the guide strand were the most effective vis-a-vis selective mutant sequence knockdown not having a significant effect on wild-type transcripts, whereas substitutions at positions 7, 8, 9 and 11 reduced wild-type expression as well (S2C Fig). Position 3 and 4 substitutions for G12V, G12R and G12C were constructed and similarly tested; the comparative results are shown in Fig 2D. The results of the screening effort are summarized in S1 Table. Triplex bi-shRNA-KRAS mut constructs can effectively and specifically knockdown KRAS mut expression without affecting KRAS wt expression in cultured cells
Given that the majority of oncogenic KRAS mutations are at codons 12 and 13, we designed a single transcription unit capable of a broadened range of KRAS mutant knockdown. Two sets of triplex knockdown vectors were constructed; one for G12D, G12V and G12R (51%, 30% and 12% of PDAC KRAS mutations, respectively) and another one for G12C, G12D and G12V (prevalent in colorectal and lung adenocarcinoma [17] ). The most effective and discriminating of the G12D, G12V, G12C and G12R knockdown bi-shRNA cassettes were included in the triplex constructs; the guide strand location of each mutated nucleotide at positions 3, 4, 3 and 4, respectively. We also evaluated the polycistronic miR-17-92 cluster backbone [designated constructs 131 (bi-shRNA Using the dual reporter system, we demonstrated that all triplex constructs produced selective G12D, G12V, G12C and G12R knockdown albeit with varied efficiency (Fig 3B) . For G12D and G12R, all four constructs were effective, although the latter was less so than the G12R specific bi-shRNA construct. Construct 131 was KRAS G12D heterozygous PANC1 cells were co-transfected with both knockdown and neomycin resistance expression vectors and then selected for G418-resistant stably transformed cells for Restriction Fragment Length Polymorphism (RFLP) assay to discriminate KRAS mut from KRAS wt (see S3C Fig) . Non-transformed cells, empty vector cells and non-specific G12V knockdown vector transformed cells all showed mutant transcript comprising 80-84% of total KRAS transcripts ( Fig 3C, lanes 1, 2 and 7 ). There was proportionally less mutant transcript (63-70%) with constructs 129 and 130 (Fig 3C, lanes 3 and 4) , whereas constructs 131 and 132 reduced the mutant transcript proportion to 9-12% of the total or 10.7-14.3% of that seen with the empty vector mutant (Fig 3C, lanes 5 and 6) . Interestingly, the total amount of KRAS transcript (mutant + wild-type) was the same in control and knockdown cells. . Based on in vitro activity (Fig 3C) , 5 μg or 25 μg per infusion of the bi-shRNA KRAS fusogenic lipoplex constructs 131 or 132 were administered via slow tail vein injection twice weekly for four weeks. The lipoplex formulation was freeze-dried and stored at 4˚C, then reconstituted and filtered prior to each application. Tumor growth was inhibited by both constructs in a dose-dependent manner, with 132 being the most effective (Fig 4A) . Treatments were well tolerated and weight loss was not observed. Tumor sampling confirmed intratumoral plasmid delivery and copy number correlation with administered dose (Fig 4B) . We postulate that the discrepancy in delivery and consequent decreased growth inhibition of construct 131 resulted from the re-constitution and filtration process of the freeze-dried formulation (Fig 4A, groups 3 and 4) .
Treated tumor samples show KRAS mutant specific knockdown and activation of EGFR signaling in vivo
Tumors were sampled from each treatment group at two days after the sixth treatment. Tumors were preserved with Qiagen AllProtect after harvesting and subsequently stored at -20˚C before processing for molecular analysis. One half of each preserved tumor was analyzed by RFLP to determine the wild-type to mutant KRAS mRNA transcript ratio. Empty liposome treated group 2 and construct 132 lipoplex (S3B Fig) treated groups 5 and 6, were examined and compared ( Fig  5A) . The WT/mutant transcript ratio of the empty liposome control treated group was approximately 0.25 (20%/80%); very much the same as for the PANC1 cells in vitro (Fig 3C) . The ratios in treatment group 5 (construct 132, 5 μg) ranged from 0.57 (36.14%/63.86%) to 1.9 (65.68%/ 34.32%); in the higher dose group (group 6; construct 132, 25 μg) the ratios were 3.6 (78.37%/ 21.63%), 5.8 (85.23%/14.77%) and no detectable mutant transcripts in sample 6A. KRAS mut basal signaling through the RAF/MEK/ERK pathway differentially regulates EGFR tyrosine and threonine autophosphorylation resulting in negative feedback control as demonstrated in a variety of KRAS mutated tumors [18] [19] [20] [21] [22] . Therefore, we examined the in vivo PANC1 mouse xenograft tumors (used for RFLP) to document the pattern of EGFR autophosphorylation (Western immunoblot). The total EGFR expression level in treated tumors averaged less than a 2-fold difference compared to untreated tumors (Fig 5B, panel c) .
On the other hand, in the construct 132 treated group there was a significant increase in the activating Y1068 EGFR phosphorylation site (Fig 5B, panel b) as well as in EGFR tyrosine phosphorylation sites Y1045, Y1068 and Y1125 (Fig 5C and S5A Fig) . We also examined MEK, ERK and AKT expression and phosphorylation (S5B Fig). pMEK and pERK were somewhat higher in higher dose treated tumors (S5C Fig, panel a, treatment groups 4 and 6) but without change in pAKT at S473 and only slightly lowered at site T308 (S5D Fig). Protein levels for ERK and AKT were slightly lower (S5D Fig). Differing from most reported in vitro knockdown studies [7, [23] [24] [25] , total RAS protein expression was about the same for treated versus untreated group (Fig 5B, panel a) . The absence of non-target KRAS wt knockdown minimizes the risk of toxicity.
Discussion
The overall mutational frequency of KRAS in cancer is 22% but with non-uniform distribution amongst different cancer types. Greater than 90% of PDAC carry KRAS mutations (with a relatively high mutant allele specific imbalance) and the mutation frequency in lung and colorectal cancer are approximately 30-50% and 40-50%, respectively (COSMIC database). KRAS isoform specific mutation frequency likewise varies with cancer type, as do downstream signaling processes. This report demonstrates a novel purposefully designed KRAS multi-mutation genotype specific knockdown moiety with the potential for a systemically delivered therapeutic approach in a majority of patients with pancreas cancer. Previous studies with PC-7 (KRAS G12V/G12V
) and PANC1 (KRAS G12D/wt ) xenografts have shown that siRNA vectors targeting KRAS codon-12 mutations can be effective in reducing tumor growth when injected intratumorally [26] . Others have extended this approach to humans by combining an intratumoral siRNA vector with systemic chemotherapy to treat locally advanced, unresectable pancreatic cancers [27] . This was shown to be safe, well tolerated and with preliminary demonstration of clinical benefit; i.e. prolonged tumor control, shrinkage and biomarker reduction. However, given the high rate of early metastagenicity of pancreatic cancer and the advanced stage at diagnosis, local intratumoral injection of siRNA vectors is not a viable option for the majority of PDAC patients. AZD4785, an antisense oligonucleotide that indiscriminately targets KRAS mut and KRAS wt achieves effective mutant and wild-type knockdown both in vitro and in vivo by systemic delivery without demonstrable adverse effects [28] . Although the authors suggest that NRAS and/or HRAS compensate for KRAS wt knockdown, it remains unclear whether or not the compartmentalization and functional specificity of the RAS isoforms will allow effective and safe clinical translation of this approach [29] [30] [31] . Both siRNA-and shRNA-mediated target gene expression knockdown have been shown to distinguish single nucleotide differences between alleles [32] [33] [34] . The position of the single nucleotide difference on the guide strand and the type of nucleotide matches are important factors determining efficacy. For siRNA, Schwarz et al. have shown that mismatches at guide strand positions 5, 9, 10, 12, 13 and 16 were most effective for differential expression knockdown, and that purine to purine mismatches are more discriminating than other mismatch types [32] . Specificity differences due to nucleotide positioning on the guide strand are possibly ascribable to target sequence composition, use of siRNA vs. shRNA, and/or different assay methods [32] [33] [34] [35] . Rather than the seed region (proposed sequence recognition region), the central region, which contains the cleavage site for cleavage-dependent RNAi, was the most consistent site for sequence selectivity. Almost all KRAS mutant specific knockdown publications place the mutant sequence at the central region [23-25, 27, 36] . In addition to the central region, positions 4 and 16 of the guide strand were also found to be useful in sequence distinction [34, 35, 37] . Insofar as bi-shRNA-KRAS mut utilizes both cleavage-dependent and cleavageindependent mechanisms, we decided to use the systematic tiling strategy to interrogate the positional effect that would result in the most effective, discriminatory, mutant-specific KRAS knockdown. Unlike most assay systems used by others that either attach the target sequence at the 3' end of a reporter gene or attach the reporter sequence at the carboxyl terminus of a target gene or in polycistronic fashion, we inserted the KRAS coding sequence of the first 17 amino acids at the amino terminus of reporter genes to mimic the natural target gene sequence location with respect to both transcription and translation. Additionally, we placed both wild-type and mutant sequences on one dual luciferase reporter expression vector in order to compare WT and mutant knockdown in the same cell and environment. The insertion of the target sequence at the amino terminus did not affect the reporter gene expression. Positions 3 and 4 of the guide strand in the seed region rather than in the central region were the most discriminating. Notably, our in vitro growth inhibition study found placing the mutated nucleotide at the central region not only affected KRAS G12D mutation cells (PANC1), but also KRAS wt cells (HEK293). That there was no growth effect for KRAS wt HT29 cells may due to inefficient in vitro transfection. The results from reporter assays were successfully translated to both in vitro and in vivo studies that showed effective knockdown of the mutant transcript without affecting the wild-type transcript in a native environment. Onco-relevant RAS downstream signaling is complex and appears to be primarily mediated via three effector pathways: 1) Raf-MEK-ERK, 2) PI3k-AKT-mTOR, and 3) RalGEF-Ral with extensive pathway cross talk and regulatory feedback pathways [18] [19] [20] [21] [22] . Pathway utilization patterns have been shown to be mutation specific. For example, NSCLC cell lines with KRAS G12D show activated PI3k and MEK whereas those with KRAS G12C and KRAS G12V show activated Ral and decreased AKT [38] . In addition, pathway utilization patterns are also tumor type context specific. MEK/ERK inhibition in lung adenocarcinoma lines with KRAS G12C decreases EZH2 expression but is without affect in cell lines with KRAS
G12V
. On the other hand, MEK/ERK inhibition decreases EZH2 expression in colon and pancreatic cancer lines with both KRAS G12C and KRAS G12V [39] . There are also data indicating the potential therapeutic relevance of regulatory feedback systems within these pathways. As an example, constitutively active KRAS mut regulates basal MEK signaling [7, 40] , which in turn has a negative feedback effect on EGFR activity by enhancing inhibitory phosphorylation (e.g., T669) and relieving activating phosphorylation (e.g., Y1068, Y1069, and Y1125) at functionally specific binding sites [14, 24, 40] . Consequently, KRAS mut downregulation facilitates activated EGFRmediated RAS wt -GDP!RAS wt -GTP configuration as seen in mut/WT cell lines and increases NRAS-GTP levels in mut/WT and mut/-cell lines [14, 40] . In addition to being heteroallelic (KRAS G12D/wt ) PANC1 cells exhibit higher EGFR copy number than other pancreatic cancer cell lines (PANC1 > MIA PaCa-2 > Capan-2). Data from our in vivo mutant-specific bishRNA treated PANC1 tumors show significantly increased p-EGFR with phosphorylation at Y1068 (Y1069), Y1045 and Y1125 sites, compared to vehicle treated or untreated tumors, without significant changes in total EGFR protein (clearly demonstrating enhanced tyrosine kinase activity due to post-translational modification induced activation rather than to increased protein expression). These data, as well as significant differential gene expression patterns (which will be presented in a separate paper) confirm that expression of the mutant KRAS allele was effectively and specifically suppressed. The consequent reactivation of EGFR signaling suggests a potential therapeutic benefit from combinatorial bi-shRNA KRAS mut and EGFR inhibition.
The RFLP data reveal that whereas the stable KRAS mut mRNA was significantly repressed in treated tumor and PANC1 cells in vitro the KRAS wt mRNA population is proportionally increased. These RFLP mRNA data are consistent with the lack of effect of our knockdown constructs on total KRAS protein, e.g., group 6 in Fig 5B, panel a, despite > 80% suppression of the mutant KRAS allele (Fig 5A) . These findings differ from other KRAS mutant specific knockdown studies that show reduction of total KRAS protein [23] [24] [25] [44, 45] , and 5) the stochastic, non-determinant loss of KRAS mut stem cells [44] . A major obstacle thus far preventing translation of RNAi technology to the clinic has been lack of effective systemic delivery comprising distribution, metabolism/elimination and tissue/ Although a freeze-dried formulation has the advantage of long-term stability allowing for storage and transport, heterogeneity and inconsistency in reconstituted material is problematic. In our experience the physical properties of the reconstituted material vary from batch to batch, often resulting in larger aggregates of test agents which require an additional filtration process to eliminate large particles (1, panel A) . This makes it difficult to determine the concentration of the actual delivered final product. Additionally, batch-to-batch variation is difficult to control. In our initial tests of constructs 131 and 132, in vitro (PANC-1) studies showed both constructs capable of selective knockdown of the KRAS mutant allele expression without affecting wild-type allele whereas the in vivo study showed that construct 131 was not as effective as 132. Subsequent analysis of intratumoral DNA revealed that 131 was not as efficiently delivered as 132, supporting the inconsistency of the freeze-dried formulation. We have since developed a new lipoplex formulation process using the ethanol injection method and are in the process of completing optimization studies prior to GMP product manufacturing and large animal toxicology studies. The resulting product has a narrower volumetric range with a smaller average diameter, homogenous physical properties ( 
